SETting OP449 into the PP2A-activating drug family.

SETting OP449 into the PP2A-activating drug family.

Item
http://www.wikidata.org/entity/Q43094665
From the Biology of PP2A to the PADs for Therapy of Hematologic MalignanciesCardamonin Suppresses TGF-β1-Induced Epithelial Mesenchymal Transition via Restoring Protein Phosphatase 2A ExpressionOverexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies.Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia.Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth.Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications
P2860

SETting OP449 into the PP2A-activating drug family.

Item
http://www.wikidata.org/entity/Q43094665
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
SETting OP449 into the PP2A-activating drug family.
@en
SETting OP449 into the PP2A-activating drug family.
@nl
type
label
SETting OP449 into the PP2A-activating drug family.
@en
SETting OP449 into the PP2A-activating drug family.
@nl
prefLabel
SETting OP449 into the PP2A-activating drug family.
@en
SETting OP449 into the PP2A-activating drug family.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P932
P356
P1433
P1476
SETting OP449 into the PP2A-activating drug family.
@en
P2093
P2860
P304
P31
P356
10.1158/1078-0432.CCR-14-0166
P407
P433
P478
P577
P698
P932